Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 known ✓ | Q9Y5N1 | 1/20 | 0.53 |
| ▸ | CYP19A1 known ✓ | P11511 | 3/20 | 0.39 |
| ▸ | MAOB known ✓ | P27338 | 1/20 | 0.39 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.43 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.39 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | CDC7 | O00311 | 1/20 | 0.37 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.37 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL690958 | 0.98 | HRH3 (0.54) | HRH3LOXL2CYP2A6SAE1UBA2 | |
| SCHEMBL28833064 | 0.93 | HRH3 (0.50) | HRH3LOXL2CYP2A6SAE1UBA2 | |
| SCHEMBL19877208 | 0.86 | KCNJ1 (0.42) | HRH3LOXL2CYP2A6KDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL9382673 | 0.76 | TAAR1 (0.46) | HRH3CYP1A2CYP2D6HPGD | |
| SCHEMBL6526163 | 0.75 | CYP19A1 (0.41) | HRH3LOXL2CYP2A6KDM4EALDH1A1 | |
| SCHEMBL3915675 | 0.74 | CYP3A4 (0.50) | HRH3LOXL2ALDH1A1CYP19A1MAOB | |
| SCHEMBL7427842 | 0.74 | ESR1 (0.50) | KDM4EALDH1A1HTT | |
| SCHEMBL10799066 | 0.74 | HTR2C (0.42) | LOXL2ALDH1A1HPGD | |
| SCHEMBL835981 | 0.74 | TAAR1 (0.47) | HRH3ALDH1A1CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL29002885 | 0.73 | HRH3 (0.53) | HRH3LOXL2CYP2A6SAE1UBA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8198460-B2 | Process for preparation of letrozole and its intermediates | FRESENIUS KABI ONCOLOGY LTD. (IN) | 2012-06-12 | — | — | US | claimed |
| EP-2212301-B1 | AN IMPROVED PROCESS FOR PREPARATION OF LETROZOLE AND ITS INTERMEDIATES | FRESENIUS KABI ONCOLOGY LTD (IN) | 2012-02-29 | — | — | EP | claimed |
| US-20100234617-A1 | PROCESS FOR PREPARATION OF LETROZOLE AND ITS INTERMEDIATES | FRESENIUS KABI ONCOLOGY LTD. (IN) | 2010-09-16 | — | — | US | claimed |
| EP-2212301-A1 | AN IMPROVED PROCESS FOR PREPARATION OF LETROZOLE AND ITS INTERMEDIATES | Fresenius Kabi Oncology Limited (IN) | 2010-08-04 | — | — | EP | claimed |
| WO-2009069140-A1 | AN IMPROVED PROCESS FOR PREPARATION OF LETROZOLE AND ITS INTERMEDIATES | DABUR PHARMA LIMITED (IN) | 2009-06-04 | — | — | WO | claimed |
| US-8198460-B2 | Process for preparation of letrozole and its intermediates | FRESENIUS KABI ONCOLOGY LTD. (IN) | 2012-06-12 | — | — | US | disclosed |
| US-8198460-B2 | Process for preparation of letrozole and its intermediates | FRESENIUS KABI ONCOLOGY LTD. (IN) | 2012-06-12 | — | — | US | disclosed |
| EP-2212301-B1 | AN IMPROVED PROCESS FOR PREPARATION OF LETROZOLE AND ITS INTERMEDIATES | FRESENIUS KABI ONCOLOGY LTD (IN) | 2012-02-29 | — | — | EP | disclosed |
| EP-2212301-B1 | AN IMPROVED PROCESS FOR PREPARATION OF LETROZOLE AND ITS INTERMEDIATES | FRESENIUS KABI ONCOLOGY LTD (IN) | 2012-02-29 | — | — | EP | disclosed |
| US-20100234617-A1 | PROCESS FOR PREPARATION OF LETROZOLE AND ITS INTERMEDIATES | FRESENIUS KABI ONCOLOGY LTD. (IN) | 2010-09-16 | — | — | US | disclosed |
| US-20100234617-A1 | PROCESS FOR PREPARATION OF LETROZOLE AND ITS INTERMEDIATES | FRESENIUS KABI ONCOLOGY LTD. (IN) | 2010-09-16 | — | — | US | disclosed |
| EP-2212301-A1 | AN IMPROVED PROCESS FOR PREPARATION OF LETROZOLE AND ITS INTERMEDIATES | Fresenius Kabi Oncology Limited (IN) | 2010-08-04 | — | — | EP | disclosed |
| EP-2212301-A1 | AN IMPROVED PROCESS FOR PREPARATION OF LETROZOLE AND ITS INTERMEDIATES | Fresenius Kabi Oncology Limited (IN) | 2010-08-04 | — | — | EP | disclosed |
| WO-2009069140-A1 | AN IMPROVED PROCESS FOR PREPARATION OF LETROZOLE AND ITS INTERMEDIATES | DABUR PHARMA LIMITED (IN) | 2009-06-04 | — | — | WO | disclosed |
| WO-2009069140-A1 | AN IMPROVED PROCESS FOR PREPARATION OF LETROZOLE AND ITS INTERMEDIATES | DABUR PHARMA LIMITED (IN) | 2009-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234617-A1 | PROCESS FOR PREPARATION OF LETROZOLE AND ITS INTERMEDIATES | CYP19A1, CYP4B1, CYP3A4 | HRH3 3971/4885CYP19A1 1/4885MAOB 244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.